ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Fisher and Redmond Subject Of Misconduct Investigation; ORI

May 6, 1994

Letter to the Editor: Could Managed care Cause Drop In Accrual In Suramin Trial?

January 5, 1996

NCI Bypass Budget Published, Seeks $2.7 Billion In FY98

June 14, 1996

Funding opportunities listed.

June 25, 2004

Boundary; Opponents Of CMS Policy Step Up The Fight.

November 9, 2007

Group Chairmen Object To “Directive” Language In Proposed Intergroup Study Guidelines

January 13, 1984